Log in
The Basidio Molecular Toolkit developed at the University of Bristol has enabled the pharmaceutical industry to achieve the efficient genetic manipulation of a group of basidiomycete fungi (mushrooms and toadstools) and thereby produce medically important antibiotics and proteins cost-effectively. For example, GlaxoSmithKline's collaboration with the Bristol team saved 70,000 hours of research and development in getting a natural antibiotic called pleuromutilin to market. In China, the system is used to produce medicinal anti-cancer proteins from fungi in commercially viable quantities. In addition, government agricultural research programmes in the US and Ireland have adopted the toolkit to increase the efficiency of their search for disease-resistant crops in the interests of farmers, consumers and economies.
Impact: Economic: Genomic selection has revolutionised, and is now standard practice, in the major dairy cattle, pig and chicken breeding programmes, worldwide and provides multiple quantifiable benefits to breeders, producers, consumers and animals.
Significance: Increased food production world-wide
Beneficiaries: Breeding companies, primary producers, consumers, livestock.
Attribution: Work led by Haley and Woolliams (Roslin Institute now part of UoE).
Reach: Methodologies applied worldwide in livestock improvement, and more recently applied in human genetics and plant breeding.
Research using novel techniques of genetic marker-aided selection enabled the development of new high yield, disease- and drought-resistant pearl millet hybrids, of which HHB67-Improved was released throughout India. HHB67-Improved is the first product of marker-assisted breeding to reach cereal producers in India and has spread rapidly since its release, preventing yield losses to downy mildew of up to 30% (valued at £7.8M) per year, and providing £2.6M additional annual grain yield. By 2011, it was grown on over 700,000 ha and currently three million people have improved food security as a direct result of this international development focused work.
The International HapMap project was a major international research collaboration to map the structure of common human genetic variation across populations from Europe, Asia and Africa. Mathematical Scientists from the University of Oxford played key roles in the development of statistical methods for the project, along with its overall design and management of the International HapMap Project.
Companies have used HapMap as the primary resource to design genome-wide microarrays to make novel discoveries in, for example, pharmacogenetic studies. The size of this market is estimated at $1.25 billion.
One novel discovery has led to a genetic test that is predictive of sustained viral suppression in patients treated for chronic hepatitis C. An estimated 2.7 to 3.9 million people are affected by HCV infection. This test is sold commercially by the company LabCorp and is a significant contributor to the company's testing volume. Finally, the project has been important in widening the public understanding of genetic variation.
Dairy-cow herds in the UK and overseas, together with the dairy farming industry, are benefiting from strategic animal-husbandry changes and lameness-control programmes underpinned by research undertaken at the University of Bristol since 1997. The dissemination by the UK Dairy Levy Board of national Standardised Lameness Scores (the DairyCo Mobility Scoring system, launched in 2008) and of Husbandry Advisory Tools (the DairyCo Healthy Feet Programme, launched in 2011) was a direct result of Bristol's work. It has led to the widespread adoption of lameness scoring as a farm-management tool, the inclusion of lameness assessment within certification schemes and a nationwide network of trained `mobility mentors'. Where implemented, this advisory support has resulted in a significant drop in lameness prevalence, thereby improving welfare and reducing the economic losses associated with treating and culling lame cows. Successful engagement with industry groups throughout the research process has ensured that scientific outputs have been rapidly implemented within the farming community. This approach has been adopted internationally with the scoring system being used by Europe's largest dairy company and a modified version is also being promoted by the New Zealand dairy industry.
Foal Immunodeficiency Syndrome (FIS) is an emerging fatal inherited equine disease which has caused much concern in the equine industry. Research at the University of Liverpool (UoL) into the genetic basis of this disease has identified the genetic mutation and developed a carrier test which led to equine population screening to understand the spread of this disease (>40% adult carriers in one breed, Fell ponies) and provided a tool for vets and owners to design selective breeding programmes to eradicate the disease. Since the introduction of the test in 2010, the number of cases has drastically fallen (only 1 detected in any breed in 2012) and FIS spread into other breeds is now considered most unlikely.
Oats are recognised as a healthy grain reducing the risk of coronary heart disease and as a valuable grain for livestock feed. Research within BEAA has provided the genetic, physiological and agronomic knowledge that underpins the breeding of high yielding husked and naked oat varieties that meets the needs of end-users in the human food and livestock sectors. BEAA bred oat varieties account for approximately 65% of the UK market and have a significant impact on health and welfare, the economy and on production and support the expanding instant oat breakfast market sector that alone is worth £160million per annum.
Research conducted at the University of Bristol between 2002 and 2006 directly influenced a significant commercial decision about use of a food additive to aid appetite control, which protected consumers from an ineffective product. Concerns about increasing levels of obesity worldwide and the toll this takes not only on human health but on health care costs, have led to the development of food ingredients that satisfy hunger for longer (enhance satiety). One such major new ingredient, Fabuless, which is owned by DSM (Dutch State Mines), a leading global manufacturer of food ingredients, was being considered by Unilever for inclusion in its range of diet foods. DSM and Unilever contacted Professor Peter Rogers, who is known for his novel methods for the experimental study of appetite control, to test the effectiveness of Fabuless. Rogers demonstrated no satiety effect of Fabuless when consumed in realistic products, which caused Unilever to abandon Fabuless as a potential food ingredient in 2009. Publication of the research also meant that other food manufacturing companies and regulatory authorities were informed about the ineffectiveness of Fabuless.
Bacteria of the Clostridium genus are of pathogenic, medical and industrial importance. Development by University of Nottingham School of Life Science researchers of three patented methods for genetic manipulation of clostridial species has led to licensing agreements for commercial exploitation of the methodology to enhance strains for chemical commodity and biofuel production and for targeted cancer therapy. These methods are providing significant world-wide impact by facilitating commercial R&D investment and technology developments in fields ranging from healthcare, through chemicals manufacture, to the environment.
In genetic studies of human disease it is now routine for studies to collect genetic data on thousands of individuals with and without a particular disease. However, the genetic data collected is incomplete, with many millions of sites of the genome unmeasured. The novel methods and software (IMPUTE) developed by researchers at the University of Oxford predict unobserved genetic data using reference datasets.
IMPUTE has been adopted by the company Affymetrix in the design of custom genotyping chips. Affymetrix recently won the tenders by the UK Biobank and UKBiLEVE studies to genotype >500,000 participants, with a total study cost of ~£25M. The company states that IMPUTE gave their project bid a significant competitive advantage. Affymetrix also purchased the IMPUTE source code for £250,000. In addition, Roche Pharmaceuticals have used the software in their research on the genetic basis of drug response. The use of imputation has saved Roche ~$1,000,000.